Ustekinumab for the treatment of moderate to severe psoriasis
| Status: |
History |
| Expected date of issue: |
September 2009 |
| Referral date: |
June 2008 |
| Wave: |
18 |
| Process: |
STA |
| Topic area:
|
NICE project team
| Executive Lead: |
Peter Littlejohns
|
| Technical Lead: |
Sally Gallaugher
|
| Communications manager: |
Tonya Gillis
|
| Project manager: |
Bijal Joshi
|
Provisional schedule
| Closing date for invited submissions / evidence submission: |
08 January 2009 |
| 1st appraisal committee meeting: |
22 April 2009 |
| 2nd appraisal committee meeting |
24 June 2009 |
Consultees and Commentators
|
| Consultees |
Commentators (no right of appeal) |
|
Manufacturers/sponsors
- Janssen-Cilag (ustekinumab)
Patient/carer groups
- Afiya Trust
- Age Concern England
- Black Health Agency
- British Ethnic Health Awareness Foundation (BEHAF)
- Changing Faces
- Chinese National Healthy Living Centre
- Confederation of Indian Organisations
- Counsel and Care
- Equalities National Council
- Help the Aged
- Let's Face It
- Muslim Council of Great Britain
- Muslim Health Network
- Psoriasis Association
- Psoriasis and Psoriatic Arthritis Alliance
- Skin Care Campaign
- South Asian Health Foundation
- Specialised Healthcare Alliance
Professional groups
- British Association for Services to the Elderly
- British Association of Dermatologists
- British Dermatological Nursing Group
- British Geriatrics Society
- British Skin Foundation
- Primary Care Dermatology Society
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine – Intellectual Disabilities Forum
- United Kingdom Clinical Pharmacy Association
Others
- Department of Health
- Dorset PCT
- Sandwell PCT
- Welsh Assembly Government
|
General
- Age Concern Cymru
- Board of Community Health Councils in Wales
- British National Formulary
- Department of Health, Social Services and Public Safety for Northern Ireland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Public Health Service for Wales
- NHS Alliance
- NHS Confederation
- NHS Purchasing and Supply Agency
- NHS Quality Improvement Scotland
- Scottish Medicines Consortium
Comparator manufacturers
- Abbott Laboratories (adalimumab)
- Schering-Plough (infliximab)
- Merck Serono (efalizumab)
- Wyeth Pharmaceuticals (etanercept)
Relevant research groups
- British Epidermo-Epidemiology Society
- Centre of Evidence-based Dermatology, University of Nottingham
- MRC Clinical Trials Unit
- National Institute of Health Research
- Policy Research Institute on Ageing and Ethnicity
- Research Institute of the Care of the Elderly
- Skin Research Centre, University of Leeds
- Skin Treatment and Research Trust (START
- United Kingdom Clinical Research Network
Evidence Review Group
- Southampton Health Technology Assessment Centre (SHTAC), University of Southampton
- National Institute for Health Research Health Technology Assessment Programme
Associated Guideline Groups
Associated Public Health Groups
|
|
Key documents
|
|
|
This page was last updated: 14 August 2009 |